Marisca Marian
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care.
Journal: JCO precision oncology
Published: September 19, 2025
Cost-effectiveness analysis of regorafenib dose optimization for refractory metastatic colorectal cancer.
Journal: Journal of medical economics
Published: April 23, 2025
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis.
Journal: JCO precision oncology
Published: June 29, 2023
Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
Journal: JCO precision oncology
Published: January 23, 2023
Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types.
Journal: Cancer management and research
Published: April 21, 2021
Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors.
Journal: JCO precision oncology
Published: February 26, 2021
Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: January 24, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026